NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM
National Institutes of Health · NIH NCI
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026R00109 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
THIS EDIT IS TO POST AMENDMENT #2. AMENDMENT #2 IS TO remove the Data Management Sharing Plan requirement and all references under Sections 5.9 Management and Sharing of Research Data, 6.1 Evaluation Process, Evaluation of Data Management and Sharing Plan, 8.5 Technical Proposal Content (I) Scientific Data Sharing. The deadline for receipt of proposals remains unchanged at 5:00pm, September 21, 2026. All other terms and conditions of the solicitation remain unchanged. PLEASE SEE ATTACHED AMENDMENT #2 PDF. ORIGINAL SOLICITATION DESCRIPTION: The National Cancer Institute (NCI) invites small busi… (show all)
ness concerns to submit research proposals under this Phase I Small Business Innovation Research (SBIR) contract solicitation. Firms with the capability to conduct research and development (R&D) in the health-related topic areas referred to below and described more fully in Section 11.0, and to commercialize the results of that R&D, are encouraged to participate. The topic areas that are being sought under this solicitation are: Topic 1: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. For this solicitation rare cancers with a 5-year survival rate of less than 50% are encouraged. Topic 2: Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation, rare cancers with a 5-year survival rate of less than 50% are encouraged. The National Cancer Institute is soliciting proposals from small business concerns who are looking for an opportunity to perform a few key activities to demonstrate proof-of-concept and feasibility of untested but potentially transformative, game-changing research and development (R&D) technologies to help cancer patients, providers and caregivers, in conjunction with Small Business Innovation Research (SBIR) program objectives. The NCI has established a high-risk, high-reward SBIR �Innovative Concept Award� Program for this purpose. Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror�s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Note: Non-exempt Human subjects research will not be supported under this solicitation. Phase I Concept Award contractors will be informed of the opportunity to apply for Phase II. Only one Phase II award may result from a single Phase I SBIR contract. The United States Department of Health and Human Services (HHS) is not obligated to make any awards under this solicitation. All awards are subject to the availability of funds. HHS is not responsible for any monies expended by the offeror before award of any contract.
Who won similar work
50 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) AN12.
Single-winner award sizes (31): middle half $8.3M to $48.0M, median $25.4M; range $10K to $100.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| FISHER BIOSERVICES INC · $TMO · $42.9B | 2 | $148.0M | Oct 7, 2026 |
| SIA PARTNERS U.S., INC. | 2 | $48.0M + 1 shared | Oct 7, 2026 |
| EMINENT SERVICES CORP | 2 | $32.9M + 1 shared | Jul 8, 2026 |
| Northwestern University 750 N. LAKE SHORE DRIVE RUBLOFF 7TH FLOOR CHICAGO IL 60611 USA | 2 | $7.7M + 1 shared | Apr 10, 2025 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD. Winston Salem NC 27157 USA | 2 | $4.9M + 1 shared | Apr 10, 2025 |
| UNIVERSITY OF MISSISSIPPI MEDICAL CENTER Jackson MS 39216 USA | 1 | $63.9M | Sep 15, 2025 |
| TEMPUS AI, INC · $TEM · $531.8M | 1 | $60.6M | Sep 17, 2025 |
| UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE BOX 359472 Seattle WA 98195 USA | 1 | $55.5M | Apr 10, 2025 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCES Winston Salem NC 27157 USA | 1 | $49.5M | Sep 15, 2025 |
| Coriell Institute for Medical Research, Inc. | 1 | $48.3M | Aug 1, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 31 past awards, $25.4M, is under 0.1% of that. 10-K
- $TEM reported $531.8M revenue in FY2025. The median single-winner award in these 31 past awards, $25.4M, is 5% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESMateriality: 0.11% of $TMO revenue (Low) SEC
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Aug 17, 2026TCG GREENCHEM INC$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug SubstancesShared multiple-award ceiling, not one company's win (Materiality N/A)
- Aug 5, 2026SIA PARTNERS U.S., INC.$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug SubstancesShared multiple-award ceiling, not one company's win (Materiality N/A)
- Aug 5, 2026ALCHEM LABORATORIES CORPORATION$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug SubstancesShared multiple-award ceiling, not one company's win (Materiality N/A)
- Aug 5, 2026TCG INC$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug SubstancesShared multiple-award ceiling, not one company's win (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $64K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 8 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 28 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.